Bismuth subsalicylate was tested in an in vivo perfused rabbit model of oesophagitis for its ability to prevent the mucosal injury caused by pepsin. Treatment efficacy was assessed under both a treatment-before-injury protocol and a treatment-after-injury protocol. Oesophageal mucosal barrier function was evaluated by measuring flux rates of H+, K+, and glucose. The degree of oesophagitis was determined by gross and microscopic examination of the mucosa by several independent observers. Results showed that under both treatment protocols, bismuth subsalicylate significantly reduced the pepsin induced disruption of the mucosal barrier, as weli as the morphologic changes. Bismuth subsalicylate when given after exposure to pepsin was also found to protect against the morphologic injury in a dose dependent manner. Experiments in vitro suggested that bismuth subsalicylate inhibits the proteolytic action of pepsin by interacting with pepsin, rather than with the pepsin substrate. We conclude that bismuth subsalicylate can protect the oesophageal mucosa against peptic injury, probably through inactivation of pepsin.
Oesophageal mucosal barrier function was evaluated by measuring flux rates of H+, K+, and glucose. The degree of oesophagitis was determined by gross and microscopic examination of the mucosa by several independent observers. Results showed that under both treatment protocols, bismuth subsalicylate significantly reduced the pepsin induced disruption of the mucosal barrier, as weli as the morphologic changes. Bismuth subsalicylate when given after exposure to pepsin was also found to protect against the morphologic injury in a dose dependent manner. Experiments in vitro suggested that bismuth subsalicylate inhibits the proteolytic action of pepsin by interacting with pepsin, rather than with the pepsin substrate. We conclude that bismuth subsalicylate can protect the oesophageal mucosa against peptic injury, probably through inactivation of pepsin. models of oesophagitis HCl inflicts little injury to the intact oesophageal epithelium, except at very high concentrations and after prolonged periods of exposure." 4 16 The bile acids typically increase the oesophageal mucosal permeability, but cause only a relatively modest degree of accompanying morphologic change.' In contrast, pepsin not only causes a significant increase in the permeability of the oesophageal mucosa, but also causes a frankly haemorrhagic, severe morphologic injury.36 The present study was therefore carried out with pepsin as the injurious agent, as it appears to be the most damaging of the components of an acidic gastroesophageal refluxate fluid.
We performed in vivo experiments to determine whether bismuth subsalicylate had protective effects against the pepsin induced oesophageal injury. Bismuth subsalicylate was tested in a treatment-before-injury and a treatment-after-injury protocol. After bismuth was found to be protective in vivo, the antipepsin activity of bismuth subsalicylate was tested in vitro to attempt to clarify its mechanism of action. Missouri) was added to the perfusate of both the control and study groups to obtain a final perfusate concentration of 1 mg/ml. The pH of the perfusate was maintained at 2-0 with HC1. At the end of this exposure period, the perfusate was discarded and the entire system, including the oesophagus, was irrigated with 100 ml isotonic saline in preparation for the subsequent flux period.
Methods
The exposure period in the treatment-afterinjury protocol was similar to that in the treatment-before-injury protocol, except that the bismuth subsalicylate was added after an initial oesophageal exposure to pepsin. The 30 minute exposure period of both the control and study groups began with perfusion of the oesophagus with a solution containing 1 mg/ml of porcine pepsin at pH 2. Ten minutes after the initiation of the exposure period, an amount of bismuth subsalicylate was added to the perfusate solution of the study groups to obtain a concentration of either 15 mg/ml, 30 mg/ml, or 60 mg/ ml of bismuth subsalicylate. Concomitantly, a quantity of pepsin and HCI was added to the perfusate to maintain the pepsin concentration at 1 mg/ml and the pH at 2. At the end of the exposure period, the perfusate was discarded and preparation was made for the flux period, as in the treatment-before-injury protocol.
The methods used during the flux period were identical for both the treatment-before-injury and the treatment-after-injury protocols. The flux solution contained 1-5 g/l polyethylene glycol (PEG, Fisher Scientific Co, Fair Lawn, NJ) 100 mCi/l 3H-PEG (New England Nuclear, Boston, Mass), and 10 mM HCl at pH 2. The osmolality was brought to 280 mosmol/l with mannitol. A 4 ml aliquot of the flux solution was taken from the reservoir at the beginning and end of the 40 minutes flux period for later analyses of K+ given, using a system previously described.36 In brief, the gross oesophagitis index was determined by the following criteria: 1 =normal appearance; 2=erythema or other abnormal appearance, but no haemorrhage; 3=non-confluent mucosal haemorrhage; 4=confluent intramural haemorrhages (Fig 1) . The microscopic oesophagitis index was scored by these Fig 3) . Similarly, the microscopic esophagitis index was reduced from 3-1 (0 2) in the untreated group to 2-1 (02) in the group treated with bismuth subsalicylate (p<0 001, Fig 3) . The efficacy of bismuth subsalicylate in reducing the oesophageal injury when administered after exposure to pepsin was similar to that observed when it was administered before the pepsin exposure. Flux rates of H+, K+, and glucose were significantly lower in the groups exposed to 15 mg/ml, 30 mg/ml, and 60 mg/ml of bismuth subsalicylate than those in the untreated control group (p<005, also reduced both the gross and microscopic esophageal indices in a dose dependent manner (Fig 4) . The gross oesophagitis index of the untreated group was 3-4 (0 2), while the treated groups were graded as 2-5 (0 2), 2-3 (0-2), and 1 8 (0-2) for bismuth subsalicylate concentrations of 15 mg/ml, 30 mg/ml, and 60 mg/ml, respectively (p<005). Similarly, the microscopic oesophagitis index was reduced from 3-4 (0-3) in the untreated group to 2-5 (0-4), [2] [3] (0 2), and 1-8 (0-3) for the same concentrations of bismuth subsalicylate (p<0 05).
Statistical analysis

In vitro experiments
In vitro experiments were done to determine if bismuth subsalicylate interacted predominantly with pepsin or its substrate. Peptic activity of acidic solutions containing either pepsin alone or pepsin plus bismuth subsalicylate was assayed in solutions containing haemoglobin substrate concentrations of 1, 2, 3, and 4 g%. The results are shown in Figure 5 . When assayed in a 1% haemoglobin substrate solution, peptic activity Haemoglobin substrate concentration (g/100 ml) 30 Current therapies for oesophagitis have traditionally included measures aimed at reducing reflux, either by increasing lower oesophageal sphincter tone or decreasing intra-abdominal pressure. Furthermore, the mainstay of therapy rests with reduction of gastric acidity. None of the existing therapies, however, are specifically directed at diminishing peptic injury of the mucosa, even though part of the efficacy of antacids may derive from a reduction of the refluxate pepsin activity through a pH rise. We recently found that the mucosal protective agent sucralfate was highly effective in preventing experimental peptic oesophagitis in the rabbit. 6 This benefit was attributed to a topical protection when it was found that sucralfate did not inactivate pepsin. The present study suggests that, through direct inactivation of pepsin, bismuth subsalicylate could provide an added benefit to a clinical therapeutic regimen which might include a combination of agents acting to prevent mucosal injury by different mechanisms.
In conclusion, these studies indicate that bismuth subsalicylate can prevent the oesophageal mucosal injury caused by pepsin. Its effect derives, at least in part, from its capacity to interact with pepsin.
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